Share on Facebook
Share on Twitter
Share on LinkedIn
Share by Email
Print
Takhzyro Generic Name & Formulations
Legal Class
Rx
General Description
Lanadelumab-flyo 300mg/2mL (150mg/mL); per vial or prefilled syringe; soln for SC inj; preservative-free.
Pharmacological Class
Plasma kallikrein inhibitor.
How Supplied
Single-dose vial—1; single-dose prefilled syringe—1 (w. needle)
Manufacturer
Generic Availability
NO
Takhzyro Indications
Indications
Prophylaxis to prevent attacks of hereditary angioedema (HAE).
Takhzyro Dosage and Administration
Adult
Give by SC inj into abdomen, thigh, or upper arm. Initially 300mg every 2 weeks. May consider 300mg every 4 weeks if well-controlled (eg, attack free) for >6 months.
Children
<12yrs: not established.
Takhzyro Contraindications
Not Applicable
Takhzyro Boxed Warnings
Not Applicable
Takhzyro Warnings/Precautions
Warnings/Precautions
Discontinue and treat if severe hypersensitivity reaction occurs. Pregnancy (during 3rd trimester). Nursing mothers.
Takhzyro Pharmacokinetics
See Literature
Takhzyro Interactions
Interactions
May increase activated partial thromboplastin time (aPTT) on assay.
Takhzyro Adverse Reactions
Adverse Reactions
Inj site reactions, upper respiratory infections, headache, rash, myalgia, dizziness, diarrhea; hypersensitivity, increased AST/ALT.
Takhzyro Clinical Trials
See Literature
Takhzyro Note
Not Applicable
Takhzyro Patient Counseling
See Literature
Images
